DRKS00012668招募中不适用
Tumorimmuntherapy associated neurological adverse events - TITAN2
Charité Campus Charité Mitte0 个研究点目标入组 200 人开始时间: 2017年7月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Treatment with immune checkpoint inhibitor
排除标准
- •Not able to consent. Persons under official or judicial custody. Contraindications for blood draw.
研究者
相似试验
已完成
2 期
Immunotherapy and Paraneoplastic Neurological SyndromesParaneoplastic Neurological SyndromesNCT02343211Assistance Publique - Hôpitaux de Paris17
进行中（未招募）
1 期
Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide.ewly diagnosed Primary Central Nervous LymphomaMedDRA version: 8.1Level: PTClassification code 10007953Term: Central nervous system lymphomaEUCTR2006-004772-12-DKordic Lymphoma Group70
进行中（未招募）
不适用
Immunochemotherapy in primary central nervous system lymphoma with rituximab, HD-MTX, HD Ara-C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide,and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide - NLG PCNSEUCTR2006-004772-12-FIordic lymphoma group70
进行中（未招募）
不适用
Immunochemotherapy in primary central nervous system lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide.ewly diagnosed Primary Central Nervous LymphomaEUCTR2006-004772-12-SEordic Lymphoma Group70
进行中（未招募）
不适用
Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunityCV2 AutoimmunityNCT06620913Hospices Civils de Lyon232